Dyadic International (DYAI) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dyadic International (DYAI) has outperformed Pluri (PLUR) over the past year, losing 60.7% versus a loss of 75.5%. Over five years, DYAI leads with a -90.8% price change compared with -95.2% for PLUR. Dyadic International is the larger company by market cap ($17.8 million vs $12.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | PLUR |
|---|---|---|
| Share price | $0.4444 | $1.00 |
| Market cap | $17.80M | $12.61M |
| 1-day change | -2.65% | -3.85% |
| YTD return | -52.72% | -66.56% |
| 1-year return | -60.67% | -75.49% |
| 5-year return | -90.84% | -95.23% |
| EPS (TTM) | $-0.23 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $4.87 |
| 52-week low | $0.34 | $0.85 |
| Distance from 52-week high | -72.23% | -79.47% |
| Analyst consensus | none | — |
| Avg. price target upside | +1137.62% | — |
| Average volume | 201.91K | 24.97K |
| Shares outstanding | 40.06M | 12.61M |
| Employees | 5 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed PLUR by 14.8 percentage points over the past year.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Healthcare · Biotechnology · 5 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
DYAI vs PLUR FAQ
Which is bigger, Dyadic International or Pluri?
Dyadic International (DYAI) is larger, with a market capitalization of $17.80M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, DYAI or PLUR?
DYAI returned -60.67% over the past 12 months, compared with -75.49% for PLUR (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.